[
  {
    "ts": null,
    "headline": "Is UPLIZNA’s EU Approval Reframing Amgen’s Rare Disease Strategy And Investment Case (AMGN)?",
    "summary": "Amgen recently reported past fourth-quarter and full-year 2025 results showing higher revenues of US$9.87 billion for the quarter and US$36.75 billion for the year, alongside increased net income and earnings per share. Shortly after those results, the European Commission approved UPLIZNA as an add-on therapy for certain adults with generalized myasthenia gravis, extending Amgen’s reach in rare autoimmune diseases with an infusible, twice-yearly maintenance option. We’ll now examine how the...",
    "url": "https://finnhub.io/api/news?id=e1cfad9d578847dfd81cf56f93135cddda412e2454d6bedda00e04b1e01fdab4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771049395,
      "headline": "Is UPLIZNA’s EU Approval Reframing Amgen’s Rare Disease Strategy And Investment Case (AMGN)?",
      "id": 139093624,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen recently reported past fourth-quarter and full-year 2025 results showing higher revenues of US$9.87 billion for the quarter and US$36.75 billion for the year, alongside increased net income and earnings per share. Shortly after those results, the European Commission approved UPLIZNA as an add-on therapy for certain adults with generalized myasthenia gravis, extending Amgen’s reach in rare autoimmune diseases with an infusible, twice-yearly maintenance option. We’ll now examine how the...",
      "url": "https://finnhub.io/api/news?id=e1cfad9d578847dfd81cf56f93135cddda412e2454d6bedda00e04b1e01fdab4"
    }
  },
  {
    "ts": null,
    "headline": "InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit",
    "summary": "InflaRx (NASDAQ:IFRX) highlighted progress on its oral C5a receptor 1 (C5aR) antagonist izicopan and outlined upcoming development plans during a presentation at the Guggenheim Outlook Biotech Summit 2026. Chief Financial Officer Thomas Taapken and investor relations executive Jan Medina also discus",
    "url": "https://finnhub.io/api/news?id=16980dfd74d9ae7befb3eacfa85ade18869c4466408d0038a89b3383749cbd14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771038128,
      "headline": "InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit",
      "id": 139092638,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "InflaRx (NASDAQ:IFRX) highlighted progress on its oral C5a receptor 1 (C5aR) antagonist izicopan and outlined upcoming development plans during a presentation at the Guggenheim Outlook Biotech Summit 2026. Chief Financial Officer Thomas Taapken and investor relations executive Jan Medina also discus",
      "url": "https://finnhub.io/api/news?id=16980dfd74d9ae7befb3eacfa85ade18869c4466408d0038a89b3383749cbd14"
    }
  }
]